American Heart Journal
Volume 157, Issue 5 , Pages 805-810.e2 , May 2009

Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran

  • Michael D. Ezekowitz, MBChB, DPhil

      Affiliations

    • Lankenau Institute for Medical Research and The Heart Center, Wynnewood, PA
    • Corresponding Author InformationReprint requests: Michael D. Ezekowitz, MD, PhD, Lankenau Institute for Medical Research and The Heart Center, Wynnewood.
    • ,
  • Stuart Connolly, MD

      Affiliations

    • Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
    • ,
  • Amit Parekh, MD

      Affiliations

    • Lankenau Institute for Medical Research and The Heart Center, Wynnewood, PA
    • ,
  • Paul A. Reilly, PhD

      Affiliations

    • Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, CT
    • ,
  • Jeanne Varrone, MD

      Affiliations

    • Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, CT
    • ,
  • Susan Wang, PhD

      Affiliations

    • Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, CT
    • ,
  • Jonas Oldgren, MD, PhD

      Affiliations

    • Uppsala Clinical Research Centre, Uppsala, Sweden
    • ,
  • Ellison Themeles

      Affiliations

    • Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
    • ,
  • Lars Wallentin, MD, PhD

      Affiliations

    • Uppsala Clinical Research Centre, Uppsala, Sweden
    • ,
  • Salim Yusuf, FRCP(c), FRSC, DPhil

      Affiliations

    • Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada

Received 24 November 2008 ,Accepted 5 February 2009.

References 

  1. Atrial Fibrillation Investigators . Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from 5 randomized controlled trials. Arch Intern Med. 1994;154:1449–1457
  2. Schwarz U, Ritchie M, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008;358:999–1008
  3. Brass L, Krumholz L, Scinto J, et al. Warfarin use following ischemic stroke among medicare patients with atrial fibrillation. Arch Intern Med. 1998;158:2093–2100
  4. Executive Steering Committee for the SPORTIF III Investigators . Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation: randomised controlled trial. Lancet. 2003;362:1691–1698
  5. Executive Steering Committee for the SPORTIF V Investigators . Ximelagatran vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. J Am Med Assoc. 2005;293:690–698
  6. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus ASA versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903–1912
  7. Samsa G, Matchar D, Goldstein L, et al. Quality of anticoagulation management among patients with atrial fibrillation. Arch Intern Med. 2000;160:967–973
  8. The Amadeus investigators . Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet. 2008;371:315–321
  9. Stassen J, Rathgen K, Zimmermann R, et al. Pharmacodynamics of the synthetic direct thrombin inhibitor BIBR 953 ZW in healthy subjects. Thromb Haemost. 2001;(Suppl.):OC2347 [Abstract]
  10. Ezekowitz M, Reilly P, Nehmiz G, et al. Dabigatran with or without concomitant ASA compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100:1419–1426
  11. The PETRO-EX Investigators . Safety and efficacy of extended exposure to several doses of a new oral direct thrombin inhibitor dabigatran etexilate in atrial fibrillation. Cerebrovasc Dis. 2006;21(Supplment 4):5, 2 [Abstract]
  12. Eriksson B, Dahl O, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement. BISTRO I. J Thromb Haemost. 2004;2:1573–1580
  13. Eriksson B, Dahl O, Büller H, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial. J Thromb Haemost. 2005;3:103–111
  14. Rosendaal F, Cannegieter S, van der Meer F, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236–239
  15. Benjamini Y, Hochberg T. Multiple hypotheses testing with weights. Scand J Statist. 1997;24:407–418
  16. Ezekowitz M. Anticoagulation interruptus: not without risk. Circulation. 2004;110:1518–1519
  17. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and ASA for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1:175–179
  18. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators . The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505–1511
  19. Stroke Prevention in Atrial Fibrillation Investigators . Stroke prevention in atrial fibrillation study. Final results. Circulation. 1991;84:527–539
  20. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet. 1993;342:1255–1262
  21. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: the Veterans Affairs Cooperative Study. N Engl J Med. 1992;327:1406–1412
  22. Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoagulation study. J Am Coll Cardiol. 1991;18:349–355
  23. Eriksson B, Dahl O, Rosencher N, et al. for the RE-NOVATE Study Group Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949–956
  24. Eriksson B, Dahl O, Rosencher N, et al. for the RE-MODEL study group A new oral anticoagulant, dabigatran etexilate, is effective and safe in preventing venous thromboembolism after total knee replacement surgery. J Thromb Haemost. 2007;5:2178–2185
  25. Brinker A, He R, Desai M, et al. Safety of ximelagatran. J Am Med Assoc. 2005;293:2859
  26. Astrazeneca Receives Action Letter From FDA For Exanta (Ximelagatran), Astrazeneca press release, 2004.
  27. Albers G on behalf of SPORTIF Investigators. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials. Am J Manag Care. 2004;10:S462–S473

 Registered clinical trial #: NCT00262600.

PII: S0002-8703(09)00129-X

doi: 10.1016/j.ahj.2009.02.005

American Heart Journal
Volume 157, Issue 5 , Pages 805-810.e2 , May 2009

Article Tools

* Image Usage & Resolution